Anneleen Lintermans

724 total citations
23 papers, 500 citations indexed

About

Anneleen Lintermans is a scholar working on Genetics, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Anneleen Lintermans has authored 23 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 11 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Oncology. Recurrent topics in Anneleen Lintermans's work include Estrogen and related hormone effects (18 papers), Menopause: Health Impacts and Treatments (5 papers) and Growth Hormone and Insulin-like Growth Factors (4 papers). Anneleen Lintermans is often cited by papers focused on Estrogen and related hormone effects (18 papers), Menopause: Health Impacts and Treatments (5 papers) and Growth Hormone and Insulin-like Growth Factors (4 papers). Anneleen Lintermans collaborates with scholars based in Belgium, United States and Germany. Anneleen Lintermans's co-authors include Patrick Neven, Robert Paridaens, Hans Wildiers, Dirk Vanderschueren, Gilbert Donders, P. Neven, Sibylle Loibl, Stefan Buchholz, V. Prasauskas and Olaf Ortmann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Anneleen Lintermans

23 papers receiving 478 citations

Peers

Anneleen Lintermans
J Cortés-Prieto Spain
Tomasz Pertyński Poland
Susan Loftus United States
Eric D. Labonté United States
Xinyu Shao China
Xiaomu Kong China
Kalina Biernacka United Kingdom
Irving Shemano United States
Yinyun Ni China
J Cortés-Prieto Spain
Anneleen Lintermans
Citations per year, relative to Anneleen Lintermans Anneleen Lintermans (= 1×) peers J Cortés-Prieto

Countries citing papers authored by Anneleen Lintermans

Since Specialization
Citations

This map shows the geographic impact of Anneleen Lintermans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anneleen Lintermans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anneleen Lintermans more than expected).

Fields of papers citing papers by Anneleen Lintermans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anneleen Lintermans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anneleen Lintermans. The network helps show where Anneleen Lintermans may publish in the future.

Co-authorship network of co-authors of Anneleen Lintermans

This figure shows the co-authorship network connecting the top 25 collaborators of Anneleen Lintermans. A scholar is included among the top collaborators of Anneleen Lintermans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anneleen Lintermans. Anneleen Lintermans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Henry, N. Lynn, Kelly Speth, Anneleen Lintermans, et al.. (2017). Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation. Clinical Breast Cancer. 17(5). 350–355.e4. 11 indexed citations
2.
Lintermans, Anneleen, Lynn Jongen, Thomas Van Brussel, et al.. (2016). Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. European Journal of Cancer. 56. 31–36. 29 indexed citations
3.
Lintermans, Anneleen, Annouschka Laenen, Diether Lambrechts, et al.. (2016). Abstract P3-07-46: CYPTAM-BRUT 3: Endometrial thickness cannot be used as a marker for tamoxifen metabolization in postmenopausal breast cancer patients. Cancer Research. 76(4_Supplement). P3–7. 2 indexed citations
4.
Lintermans, Anneleen, Lynn Jongen, Diether Lambrechts, et al.. (2016). Prospective study evaluating the effect of impaired tamoxifen metabolisation on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting.. Journal of Clinical Oncology. 34(15_suppl). 523–523. 3 indexed citations
5.
Lintermans, Anneleen & Patrick Neven. (2015). Safety of aromatase inhibitor therapy in breast cancer. Expert Opinion on Drug Safety. 14(8). 1201–1211. 22 indexed citations
6.
Neven, Patrick, et al.. (2014). Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocrine Related Cancer. 21(1). R31–R49. 49 indexed citations
7.
8.
Buchholz, Stefan, Anneleen Lintermans, Gert Bellen, et al.. (2014). Vaginal estriol–lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric. 18(2). 252–259. 31 indexed citations
9.
Lintermans, Anneleen, Hans Wildiers, Annouschka Laenen, et al.. (2014). A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Research and Treatment. 146(1). 109–116. 37 indexed citations
10.
Lintermans, Anneleen, Dirk Vanderschueren, Johan Verhaeghe, et al.. (2014). Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. European Journal of Cancer. 50(17). 2925–2931. 15 indexed citations
11.
Pauwels, Steven, Leen Antonio, Ivo Jans, et al.. (2013). Sensitive routine liquid chromatography–tandem mass spectrometry method for serum estradiol and estrone without derivatization. Analytical and Bioanalytical Chemistry. 405(26). 8569–8577. 56 indexed citations
12.
Lintermans, Anneleen, Annouschka Laenen, Ben Van Calster, et al.. (2012). Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Annals of Oncology. 24(2). 350–355. 27 indexed citations
13.
14.
Lintermans, Anneleen, Ben Van Calster, Steven Pans, et al.. (2011). Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Annals of Oncology. 22(8). 1763–1769. 36 indexed citations
15.
Lintermans, Anneleen, Patrick Neven, & Robert Paridaens. (2011). Drug safety evaluation of exemestane. Expert Opinion on Drug Safety. 10(3). 473–487. 6 indexed citations
16.
Lintermans, Anneleen & Patrick Neven. (2011). Pharmacology of arthralgia with estrogen deprivation. Steroids. 76(8). 781–785. 16 indexed citations
17.
Lintermans, Anneleen, Joke Vanderhaegen, N. Lynn Henry, et al.. (2011). P2-17-09: A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen.. Cancer Research. 71(24_Supplement). P2–17. 1 indexed citations
18.
Verhulst, Pieter–Jan, Anneleen Lintermans, Sara Janssen, et al.. (2011). GPR39, a Receptor of the Ghrelin Receptor Family, Plays a Role in the Regulation of Glucose Homeostasis in a Mouse Model of Early Onset Diet-Induced Obesity. Journal of Neuroendocrinology. 23(6). 490–500. 30 indexed citations
19.
Loibl, Sibylle, et al.. (2010). Management of menopausal symptoms in breast cancer patients. Maturitas. 68(2). 148–154. 46 indexed citations
20.
Lintermans, Anneleen, et al.. (2009). Role of the G-protein coupled receptor 39 in the pathogenesis of type 2 diabetes. Neurogastroenterology & Motility. 21. 20–21. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Cortés-Prieto Breakdown of academic impact, for papers by Tomasz Pertyński Breakdown of academic impact, for papers by Susan Loftus Breakdown of academic impact, for papers by Eric D. Labonté Breakdown of academic impact, for papers by Xinyu Shao Breakdown of academic impact, for papers by Xiaomu Kong Breakdown of academic impact, for papers by Kalina Biernacka Breakdown of academic impact, for papers by Irving Shemano Breakdown of academic impact, for papers by Yinyun Ni
Rankless by CCL
2026